- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Zivo Bioscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | ZIVO Bioscience Provides Special Letter to Shareholders | 86 | Business Wire | TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow... ► Artikel lesen | |
| ZIVO BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Zivo Bioscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Zivo Bioscience, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,270 | -0,81 % | Evotec streicht 800 Stellen - und trotzdem sehen Analysten 100% Kurspotenzial | 800 Stellen weg, Kosten explodiert, Gewinne verschoben - Evotec steckt tief in der Krise. Doch Analysten sehen mehr als 100% Kurspotenzial. Was steckt hinter dem Widerspruch? Rund 800 Stellen werden... ► Artikel lesen | |
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,000 | +1,04 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| NANOREPRO | 1,340 | -4,29 % | NanoRepro: Strukturelle Stärkung im Kerngeschäft | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die NanoRepro AG in den ersten sechs Monaten des Geschäftsjahres 2025 (per 30.6.) den Umsatz deutlich um rund 37... ► Artikel lesen | |
| BRAIN BIOTECH | 2,460 | +1,23 % | BRAIN BIOTECH AG: Stabilität als strategische Phase | ||
| CO.DON | 0,014 | -22,22 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,332 | -1,04 % | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Halle (Saale) / Munich, Germany... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 112,00 | -0,18 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer | SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,150 | -1,71 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| ALDEYRA | 1,469 | -0,17 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| DENALI THERAPEUTICS | 15,640 | -0,89 % | Denali Therapeutics Inc.: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) | First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverage... ► Artikel lesen | |
| CEL-SCI | 2,500 | -4,58 % | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 | Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive... ► Artikel lesen | |
| NOVOCURE | 9,086 | +0,35 % | Novocure Reports Positive Topline Results From Phase 2 PANOVA-4 Trial Of TTFields Therapy | WASHINGTON (dpa-AFX) - Novocure (NVCR) announced Thursday positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq)... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,381 | -0,83 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| AC IMMUNE | 2,260 | +1,35 % | AC Immune SA: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update | AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's... ► Artikel lesen |
ZIVO BIOSCIENCE INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZIVO BIOSCIENCE INC finden Sie auf Wallstreet Online.